CUSIP 03940C100COMMON STOCKACLXGBXQ4 2025
58 filings · latest Mar 6, 2026
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Gilead Sciences, Inc. | 6.72M | $438.20M |
| 2 | Paradigm Biocapital Advisors LP | 5.72M | $373.21M |
| 3 | Vanguard Group Inc | 4.08M | $266.12M |
| 4 | Fmr LLC | 3.56M | $232.36M |
| 5 | Blackrock, Inc. | 3.55M | $231.38M |
| 6 | Nea Management Company, LLC | 3.05M | $198.55M |
| 7 | Vestal Point Capital, LP | 2.92M | $190.71M |
| 8 | Sr One Capital Management, LP | 2.35M | $153.00M |
| 9 |
| 4 | Feb 24, 2026 | New Enterprise Associates 15, L.P. | 13D/A | 5.3% | — | SEC |
| 5 | Feb 23, 2026 | Gilead Sciences, Inc. | 13D | 11.5% | — | SEC |
| 6 | Feb 17, 2026 | T. Rowe Price Investment Management, Inc. | 13G/A | 18.3% | 10.56M | SEC |
| 7 | Feb 17, 2026 | Ra Capital Management, L.P. | 13G/A | 2.2% | 1.27M | SEC |
| 8 | Feb 17, 2026 | Paradigm Biocapital Advisors LP | 13G/A | 9.9% | 9.23B | SEC |
| 9 | Feb 17, 2026 | Vestal Point Capital, LP | 13G | 5.1% | 2.92M | SEC |
| 10 | Feb 5, 2026 | Fmr LLC | 13G/A | 6.2% | 3.56M | SEC |
See the full Schedule 13D/13G history for Arcellx Inc.
Unlock full history| State Street Corp |
| 2.00M |
| $130.30M |
| 10 | Citadel Advisors LLC | 1.50M | $97.81M |